All Stories

  1. Feasibility of Point-of-Care Testing for Influenza Within a National Primary Care Sentinel Surveillance Network in England: Protocol for a Mixed Methods Study
  2. ¿Qué hemos aprendido sobre rotavirus en España en los últimos 10 años?
  3. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
  4. Influenza epidemiology and influenza vaccine effectiveness during the 2015–2016 season: results from the Global Influenza Hospital Surveillance Network
  5. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
  6. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials
  7. Feasibility of Point-of-Care Testing for Influenza Within a National Primary Care Sentinel Surveillance Network in England: Protocol for a Mixed Methods Study (Preprint)
  8. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
  9. Letter to the editor regarding “Rotavirus infection beyond the gut”
  10. Rapid assessment of enhanced safety surveillance for influenza vaccine
  11. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres
  12. Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers
  13. Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study
  14. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children
  15. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment
  16. Impact of postherpetic neuralgia: A six year population-based analysis on people aged 50 years or older
  17. Influence of health literacy on acceptance of influenza and pertussis vaccinations: a cross-sectional study among Spanish pregnant women
  18. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
  19. Clinical and laboratory features of children with community-acquired pneumonia are associated with distinct radiographic presentations
  20. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009–2014
  21. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons
  22. Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17
  23. Lack of impact of rotavirus vaccines on seizure-related hospitalizations in children under 5 years old in Spain
  24. Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative
  25. Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination
  26. Letter to the Editor regarding “The role of age-sex interaction in the development of post-herpetic neuralgia”
  27. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season
  28. Random Network Models to Predict the Long-Term Impact of HPV Vaccination on Genital Warts
  29. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
  30. Economic Burden Of Herpes Zoster In Spain
  31. Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015
  32. Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009–2014
  33. Random network models to predict the long term impact of HPV vaccination on genital warts
  34. Drivers for human papillomavirus vaccination in Valencia (Spain)
  35. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain
  36. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination
  37. Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vaccine 3...
  38. Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain
  39. Antibiotic Use in Children – A Cross-National Analysis of 6 Countries
  40. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial
  41. Infecciones por virus respiratorio sincitial en adultos diagnosticados en la Comunidad Valenciana
  42. Determinants of seasonal influenza vaccination in pregnant women in Valencia, Spain
  43. Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season
  44. Rotavirus, vaccine failure or diagnostic error?
  45. Herpes Zoster-Associated Resources Consumption In Chronic Obstructive Pulmonary Disease Patients
  46. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
  47. Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications
  48. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system
  49. Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines
  50. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age
  51. Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain
  52. Studying the Herd Immunity Effect of the Varicella Vaccine in the Community of Valencia, Spain
  53. Vacuna triple vírica. Resurgimiento del sarampión en Europa
  54. Aceptabilidad de la vacuna contra el virus del papiloma humano en madres de la provincia de Valencia (España)
  55. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls
  56. Intussusception following rotavirus vaccination in the Valencia Region, Spain
  57. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
  58. Vaccine coverage estimation using a computerized vaccination registry with potential underreporting and a seroprevalence study
  59. Rotavirus vaccine effectiveness in a large cohort
  60. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination
  61. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: A randomised non-inferiority clinical trial
  62. Vacunación frente a la hepatitisB. Impacto de los programas de vacunación tras 20años de su utilización en España. ¿Es tiempo de cambios?
  63. Influenza Vaccine Effectiveness in Preventing Influenza A(H3N2)-Related Hospitalizations in Adults Targeted for Vaccination by Type of Vaccine: A Hospital-Based Test-Negative Study, 2011–2012 A(H3N2) Predominant Influenza Season, Valencia, Spain
  64. Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007–2011)
  65. Notificación de reacciones adversas a la vacuna frente al virus del papiloma humano en la Comunidad Valenciana (2007-2011)
  66. Social, economic, and health impact of the respiratory syncytial virus: a systematic search
  67. Seroprevalencia frente a sarampión, rubeola y parotiditis en personal facultativo del servicio de pediatría del Hospital Universitario y Politécnico La Fe de Valencia
  68. Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011–2012 influenza season: A comparative effectiveness study using the Valencia health care information system
  69. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants
  70. Vigilancia pasiva de la seguridad postautorización de las vacunas frente a rotavirus: sensibilidad de la notificación de invaginación intestinal
  71. Post-licensure passive safety surveillance of rotavirus vaccines: Reporting sensitivity for intussusception
  72. Author's Response Re: Letter to the Editor Re: Martínez-García R, Úbeda-Sansano MI, Díez-Domingo J, Pérez-Hoyos S, Gil-Salom M. It is time to abandon “expected bladder capacity.” Systematic review and new models for children's normal maximum voided volume
  73. “Knowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverage”
  74. Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)
  75. Re: Martínez-García R, Ubeda-Sansano MI, Díez-Domingo J, Pérez-Hoyos S, Gil-Salom M. It is time to abandon “Expected bladder capacity.” Systematic review and new models for children's normal maximum voided volumes. Neurourol Urodyn 2014;33:1092-8
  76. Ethical considerations of universal vaccination against human papilloma virus
  77. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10–17 years of age: Results from a randomised, controlled, double-blind trial
  78. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain
  79. Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)
  80. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule
  81. Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population
  82. A clinical study of a shingles (Herpes Zoster) vaccine (Live) administered by intramuscular or subcutaneous routes in adults aged≥50 years
  83. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system
  84. It is time to abandon “Expected bladder capacity.” Systematic review and new models for children's normal maximum voided volumes
  85. Sospecha de reacciones adversas a la vacuna triple vírica notificadas al Centro de Farmacovigilancia de la Comunidad Valenciana
  86. Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's diarrhea
  87. Gut Microbiota in Children Vaccinated With Rotavirus Vaccine
  88. Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin
  89. Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: A case–case comparison, case-control study
  90. Antibiotic Therapy for Pediatric Community-acquired Pneumonia
  91. The impact of childhood acute rotavirus gastroenteritis on the parents’ quality of life: prospective observational study in European primary care medical practices
  92. 13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal C–Tetanus Toxoid Conjugate and Other Routine Pediatric Vaccinations
  93. Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules
  94. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain)
  95. MF59™-adjuvanted seasonal influenza vaccine in young children
  96. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain
  97. Using random networks to study the dynamics of respiratory syncytial virus (RSV) in the Spanish region of Valencia
  98. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conj...
  99. Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain
  100. Evidencias científicas disponibles sobre la seguridad de las vacunas
  101. Cost analysis of a vaccination strategy for respiratory syncytial virus (RSV) in a network model
  102. A RANDOMIZED, MULTICENTER, OPEN-LABEL CLINICAL TRIAL TO ASSESS THE ANAMNESTIC IMMUNE RESPONSE 4 TO 8 YEARS AFTER A PRIMARY HEPATITIS B VACCINATION SERIES
  103. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries
  104. Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain
  105. ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE
  106. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes
  107. Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1–11 years
  108. Epidemiology of Herpes Zoster Infection among Patients Treated in Primary Care Centres in the Valencian Community (Spain)
  109. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years
  110. Invasive Haemophilus influenzae Disease, Europe, 1996–2006
  111. Palatabilidad de las soluciones de rehidratación oral en niños sanos de 6 a 9 años. Ensayo clínico multicéntrico, aleatorizado y simple ciego
  112. A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months
  113. Nosocomial Rotavirus Gastroenteritis in Spain
  114. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications
  115. PIN17 THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN IN FOUR EUROPEAN COUNTRIES: A STUDY IN PRIMARY CARE
  116. Calendario vacunal de la Asociación Española de Pediatría 2009
  117. Calendario vacunal de la Asociación Española de Pediatría: Recomendaciones 2009
  118. Pertussis in adults with persistent cough: a prospective follow up study in primary care
  119. Pediatric Safety Evaluation of An AS-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3–9 Years: A Phase II Study
  120. Recomendaciones de vacunación de la Asociación Española de Pediatría 2008
  121. ¿Por qué hay más empiemas pediátricos en España?
  122. Criterios de inclusión de vacunas en el calendario de la Asociación Española de Pediatría
  123. Calendario vacunal de la Asociación Española de Pediatría: recomendaciones 2008
  124. Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly
  125. Dos vacunas frente a rotavirus seguras y eficaces
  126. Rotavirus vaccines: considerations for successful implementation in Europe
  127. Economic evaluation of varicella vaccination in Spain—Results from a dynamic model
  128. Vacuna frente al virus del papiloma humano: un nuevo reto para el pediatra
  129. Incidencia y costes de la hospitalización por bronquiolitis y de las infecciones por virus respiratorio sincitial en la Comunidad Valenciana. Años 2001 y 2002
  130. Estudio de costes directos de la otitis media aguda en menores de 5 años en la Comunidad Valenciana
  131. Gripe aviar: ¿para cuándo la vacuna?
  132. ROTAVIRUS GASTROENTERITIS AMONG CHILDREN UNDER FIVE YEARS OF AGE IN VALENCIA, SPAIN
  133. Calendario de vacunación de la Asociación Española de Pediatría: recomendaciones 2006
  134. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1–11-year-old children
  135. Seroprevalence of Varicella Among Children and Adolescents in Valencia, Spain: Reliability of the Parent’s Reported History and the Medical File for Identification of Potential Candidates for Vaccination
  136. Epidemiología de la neumonía adquirida en la comunidad en menores de 5 años en la Comunidad Valenciana
  137. Immunogenicity and Reactogenicity of a Combined Adsorbed Tetanus Toxoid, Low Dose Diphtheria Toxoid, Five Component Acellular Pertussis and Inactivated Polio Vaccine in Six-Year-Old Children
  138. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age
  139. Investigación en pediatría de atención primaria: la asignatura pendiente
  140. Incidence of pertussis in persons ≤15 years of age in Valencia, Spain: seroprevalence of antibodies to pertussis toxin (PT) in children, adolescents and adults
  141. Risk factors for invasive disease among children in Spain
  142. Epidemiología e impacto de la otitis media aguda en la Comunidad Valenciana
  143. Investigación en pediatría de atención primaria: la asignatura pendiente
  144. Epidemiología e impacto de la otitis media aguda en la Comunidad Valenciana
  145. Epidemiology and economic impact of varicella in immunocompetent children in Spain.
  146. Atención a neonatos en una unidad de urgencias pediátricas
  147. Inmunización: saltos al futuro. Vacunas combinadas (II)
  148. Sistemas de información en atención primaria: ¿debemos codificar con la CIE-9-MC?
  149. Inmunización: saltos al futuro. Vacunas combinadas (I)
  150. Vacunas combinadas (I)
  151. Vacunas combinadas (II)
  152. Vacuna del meningococo, ¿necesidad de revacunaciones?
  153. Sistemas de información en atención primaria: ¿debemos codificar con la CIE-9-MC?
  154. Evolución de la enfermedad invasiva por Haemophilus influenzae tipo b en niños de la Comunidad Valenciana y su relación con las vacunas combinadas
  155. Encuesta sobre el uso racional de antibióticos en atención primaria
  156. Encuesta sobre el uso racional de antibióticos en atención primaria
  157. Epidemiology of Invasive Streptococcus pneumoniae Infections in Children in Spain, 1996–1998
  158. Encefalitis centroeuropea o transmitida por garrapatas
  159. Efectos adversos tras la vacunación con dos vacunas de polisacárido de meningococo C conjugado con CRM197, en niños de 1 a 6 años de edad. Ensayo clínico controlado
  160. Impact of Non-routine Vaccination on the Incidence of Invasive Haemophilus influenzae Type b (Hib) Disease: Experience in the Autonomous Region of Valencia, Spain
  161. Utilización de la alternancia de antipiréticos en el tratamiento de la fiebre en España
  162. Epidemiological Pattern of Meningococcal Disease in Valencia, Spain. Impact of a Mass Immunization Campaign With Meningococcal C Polysaccharide Vaccine
  163. Evaluación de la eficacia antipirética y seguridad de dos formulaciones pediátricas de ibuprofeno
  164. A cost benefit analysis of routine varicella vaccination in Spain
  165. Ibuprofen prophylaxis for adverse reactions to diphtheria-tetanus-pertussis vaccination: a randomized trial
  166. Depression in women suffering perinatal loss
  167. Adverse Events after Polysaccharide meningococcal A&C Vaccine
  168. Prenatal deficiency of phosphate, phosphate supplementation, and rickets in very-low-birthweight infants